Roche Diagnostics showcases science-driven leadership and innovation at ADLM 2025
Roche will spotlight its commitment to delivering the right test at the right time — empowering clinical decisions, simplifying operations and transforming patient outcomes across the healthcare continuum at the 2025 Association for Diagnostics & Laboratory Medicine (ADLM) Scientific Meeting and Clinical Lab Expo.
At booth 1902, Roche will showcase the cobas reagent portfolio that includes the Elecsys Alzheimer's cerebrospinal fluid (CSF) assays, aiming to more effectively detect amyloid pathology and support an Alzheimer’s disease diagnosis.
Roche will also present its full array of navify digital solutions, which securely integrate data across care settings, connecting the healthcare community and accelerating access to innovation and insights.
As part of its scientific programming, Roche is hosting two dynamic workshops led by industry experts:
- Workshop 1: Cardiovascular Risk Assessment and Lipoprotein(a): Closing Gaps in ASCVD Prevention. This workshop will explore critical gaps in awareness, testing and risk stratification related to Lp(a), with a focus on identifying and managing people with high risk for cardiovascular disease.
- Workshop 2: Innovations in Cervical-Cancer Screening and Diagnosis. This session will explore the latest advancements in cervical-cancer screening and diagnosis, including self-collection methods, updated clinical guidelines, and the evolving role of technologies such as extended HPV genotyping and home-based testing. Expert speakers will share insights on how these developments can increase awareness and expand access to regular screening across diverse populations.
